WuXi Biologics (Cayman) Beheer
Beheer criteriumcontroles 2/4
WuXi Biologics (Cayman)'s CEO is Chris Chen, appointed in Jan 2016, has a tenure of 8.83 years. total yearly compensation is CN¥96.91M, comprised of 4.1% salary and 95.9% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth HK$238.84M. The average tenure of the management team and the board of directors is 2.2 years and 7.2 years respectively.
Belangrijke informatie
Chris Chen
Algemeen directeur
CN¥96.9m
Totale compensatie
| Percentage CEO-salaris | 4.1% |
| Dienstverband CEO | 8.8yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 2.2yrs |
| Gemiddelde ambtstermijn bestuur | 7.2yrs |
Recente managementupdates
Recent updates
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar
Sep 26
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥3b |
| Mar 31 2024 | n/a | n/a | CN¥3b |
| Dec 31 2023 | CN¥97m | CN¥4m | CN¥3b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥79m | CN¥3m | CN¥4b |
| Sep 30 2022 | n/a | n/a | CN¥4b |
| Jun 30 2022 | n/a | n/a | CN¥4b |
| Mar 31 2022 | n/a | n/a | CN¥4b |
| Dec 31 2021 | CN¥51m | CN¥3m | CN¥3b |
| Sep 30 2021 | n/a | n/a | CN¥3b |
| Jun 30 2021 | n/a | n/a | CN¥3b |
| Mar 31 2021 | n/a | n/a | CN¥2b |
| Dec 31 2020 | CN¥31m | CN¥3m | CN¥2b |
| Sep 30 2020 | n/a | n/a | CN¥1b |
| Jun 30 2020 | n/a | n/a | CN¥1b |
| Mar 31 2020 | n/a | n/a | CN¥1b |
| Dec 31 2019 | CN¥25m | CN¥3m | CN¥1b |
| Sep 30 2019 | n/a | n/a | CN¥922m |
| Jun 30 2019 | n/a | n/a | CN¥831m |
| Mar 31 2019 | n/a | n/a | CN¥731m |
| Dec 31 2018 | CN¥20m | CN¥2m | CN¥631m |
| Sep 30 2018 | n/a | n/a | CN¥520m |
| Jun 30 2018 | n/a | n/a | CN¥410m |
| Mar 31 2018 | n/a | n/a | CN¥331m |
| Dec 31 2017 | CN¥24m | CN¥2m | CN¥253m |
Compensatie versus markt: Chris's total compensation ($USD13.66M) is above average for companies of similar size in the Hong Kong market ($USD640.18K).
Compensatie versus inkomsten: Chris's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Chris Chen (51 yo)
8.8yrs
Tenure
CN¥96,911,000
Compensatie
Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder & Chairman | 10.8yrs | geen gegevens | geen gegevens | |
| CEO & Executive Director | 8.8yrs | CN¥96.91m | 0.35% HK$ 238.8m | |
| Honorary President of Global Biologics Development | 9.6yrs | CN¥32.89m | 0.012% HK$ 8.1m | |
| CFO & Executive VP | 3yrs | geen gegevens | geen gegevens | |
| COO & Senior VP | less than a year | geen gegevens | geen gegevens | |
| Chief Technology Officer and Executive VP of Global Biologics Development Department | less than a year | geen gegevens | geen gegevens | |
| Chief Scientific Officer & President of Global Biologics Research | no data | geen gegevens | geen gegevens | |
| Senior VP & Head of Investor Relations | less than a year | geen gegevens | geen gegevens | |
| VP & Head of Legal Department | no data | geen gegevens | geen gegevens | |
| Chief Compliance Officer | 2.2yrs | geen gegevens | geen gegevens | |
| VP & Head of Global Human Resources | no data | geen gegevens | geen gegevens | |
| Senior VP and Head of Global BD & Alliance Management | no data | geen gegevens | geen gegevens |
2.2yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: 2269's management team is considered experienced (2.2 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder & Chairman | 10.8yrs | geen gegevens | geen gegevens | |
| CEO & Executive Director | 10.8yrs | CN¥96.91m | 0.35% HK$ 238.8m | |
| Honorary President of Global Biologics Development | 8.5yrs | CN¥32.89m | 0.012% HK$ 8.1m | |
| Independent Non-Executive Director | 1.5yrs | CN¥710.00k | 0.00063% HK$ 433.4k | |
| Member of Scientific Advisory Board | 6.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.8yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 7.5yrs | CN¥906.00k | 0.00053% HK$ 364.6k | |
| Non-Executive Director | 8.5yrs | geen gegevens | geen gegevens | |
| Non-Executive Director | 8.5yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 4.4yrs | CN¥933.00k | 0.0050% HK$ 3.4m |
7.2yrs
Gemiddelde duur
59.5yo
Gemiddelde leeftijd
Ervaren bestuur: 2269's board of directors are considered experienced (7.2 years average tenure).